eplontersen
Selected indexed studies
- Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. (JAMA, 2023) [PMID:37768671]
- Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis. (J Card Fail, 2024) [PMID:38065307]
- Eplontersen: First Approval. (Drugs, 2024) [PMID:38413492]
_Worker-drafted node — pending editorial review._
Connections
eplontersen is a side effect of
Sources
- Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. (2023) pubmed
- Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis. (2024) pubmed
- Eplontersen: First Approval. (2024) pubmed
- Eplontersen. (2006) pubmed
- Eplontersen. (2012) pubmed
- PMID:39869725 (2024) pubmed
- Eplontersen Sodium. (2024) pubmed
- Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial. (2025) pubmed
- Eplontersen: a promising breakthrough in treating hereditary transthyretin amyloidosis-related polyneuropathy. (2024) pubmed
- Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform. (2024) pubmed